Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 27, 2026 22:31 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
OtherCommon Stock | 6,851 | $75.76 | $519,031.76 |
DisclosureSEC source: 0001225208-26-002794 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Indirect · By 401(k) Disclosed balance after: 20,205 F1 · kind: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2 · balance_after: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 905 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · derivative · entry 9 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 905 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Tax withholdingCommon Stock | 339 | $74.73 | $25,333.47 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · nonDerivative · entry 6 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,094 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionCommon Stock | 905 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · nonDerivative · entry 5 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 637 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · derivative · entry 9 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 637 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 283 | $74.73 | $21,148.59 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · nonDerivative · entry 6 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,393 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 637 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · nonDerivative · entry 5 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · derivative · entry 9 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 990 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Tax withholdingCommon Stock | 440 | $74.73 | $32,881.20 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · nonDerivative · entry 6 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,986 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · nonDerivative · entry 5 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · derivative · entry 10 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 990 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 291 | $74.73 | $21,746.43 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · nonDerivative · entry 6 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,302 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 990 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · nonDerivative · entry 5 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · derivative · entry 12 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,265 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 7,865 | $74.73 | $587,751.45 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 8 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576,860 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 16,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 7 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,584,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · derivative · entry 12 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,546 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,229 | $74.73 | $91,843.17 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 8 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,792 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 7 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · derivative · entry 12 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,960 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 1,806 | $74.73 | $134,962.38 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 8 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,907 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · derivative · entry 11 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,839 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 890 | $74.73 | $66,509.70 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 8 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,244 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 7 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 1,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · derivative · entry 8 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,190 Underlying: Common Stock · 1,190 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Tax withholdingCommon Stock | 449 | $74.73 | $33,553.77 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · nonDerivative · entry 4 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,528 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionCommon Stock | 1,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · nonDerivative · entry 3 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · derivative · entry 8 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 661 Underlying: Common Stock · 661 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 296 | $74.73 | $22,120.08 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · nonDerivative · entry 4 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,039 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002139 · doc4.xml · nonDerivative · entry 3 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 1,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · derivative · entry 8 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,058 Underlying: Common Stock · 1,058 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Tax withholdingCommon Stock | 470 | $74.73 | $35,123.10 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · nonDerivative · entry 4 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,436 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Monson JonathanEVP and CFO
|
Exercise / conversionCommon Stock | 1,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002136 · doc4.xml · nonDerivative · entry 3 Monson Jonathan · CIK 0001779170 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · derivative · entry 9 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124 Underlying: Common Stock · 1,124 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 329 | $74.73 | $24,586.17 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · nonDerivative · entry 4 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,603 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 1,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002138 · doc4.xml · nonDerivative · entry 3 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · derivative · entry 11 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,524 Underlying: Common Stock · 16,524 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 7,990 | $74.73 | $597,092.70 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 6 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,568,460 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 16,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002135 · doc4.xml · nonDerivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · derivative · entry 11 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,173 Underlying: Common Stock · 3,173 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,535 | $74.73 | $114,710.55 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 6 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,475 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002133 · doc4.xml · nonDerivative · entry 5 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · derivative · entry 11 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,363 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Tax withholdingCommon Stock | 1,990 | $74.73 | $148,712.70 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,753 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:58 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002134 · doc4.xml · nonDerivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · derivative · entry 10 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,851 Underlying: Common Stock · 1,851 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 895 | $74.73 | $66,883.35 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 6 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,295 Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 22:57 UTC |
Brown Vance REVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002132 · doc4.xml · nonDerivative · entry 5 Brown Vance R · CIK 0001868243 · EVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:58 UTC |
O'Connor Padraig AndrewEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-002137 · doc4.xml · derivative · entry 7 O'Connor Padraig Andrew · CIK 0002098740 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,502 Underlying: Common Stock · 500 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.